Macrogen APAC is a wholly owned subsidiary of Macrogen, Inc. (KOSDAQ: 038290), a precision medicine biotechnology company headquartered in Korea.
Since its foundation in 1997, Macrogen has been implementing various activities in genetically engineered mouse (GEM), disease and new medicine assessment using GEM, the development of molecular diagnosis kits, target treatment research, new medicine research, and gene treatment research using stem cells and induced pluripotent stem cells for the purpose of realizing and implementing precision medicine. It has acquired more than 50 technologies, including the CRISPR-Cas9 portfolio of the Broad Institute.
The company has also been continuously supporting various research and development activities by domestic and overseas life science and medicine researchers.
